01 April 2008
Rosiglitazone in the prevention of diabetes and cardiovascular disease: Dream or reality?
Tomas Stulc, Richard CeskaMed Sci Monit 2008; 14(4): RA45-47 :: ID: 850308
Abstract
Results of the recently published DREAM trial seemingly demonstrate that the PPAR-γ agonist rosiglitazone is effective in the prevention of diabetes. However, a more detailed inspection of the trial shows that rosiglitazone is masking rather than preventing the progression to diabetes. This questionable effect was achieved at the price of unnecessarily treating approximately five subjects who would remain nondiabetic anyway for each case of “prevented” diabetes, with all the associated costs and risks. The trial also raises the unexpected possibility that rosiglitazone may substantially increase the risk of cardiovascular events, which would be particularly harmful in the high-risk patients with diabetes. This possibility is further supported by the results of several recent meta-analyses. In addition, these serious safety concerns should be carefully weighed against the weak evidence of benefit which, so far, is limited to laboratory endpoints. Therefore, rather than extending the use of rosiglitazone to the prevention of diabetes, the DREAM trial calls in question the safety of this drug as such in any patient and casts some doubt upon the whole class of PPAR-γ agonists. With respect to its wide use in clinical practice, the potential risks of rosiglitazone warrant careful investigation and, in the meantime, this drug should be used with caution.
Keywords: Diabetes Mellitus - prevention & control, Cardiovascular Diseases - prevention & control, PPAR gamma - metabolism, Risk Factors, Thiazolidinediones - pharmacology
Editorial
01 August 2022 : Editorial
Editorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 PandemicDOI: 10.12659/MSM.937927
Med Sci Monit 2022; 28:e937927
In Press
12 Aug 2022 : Clinical Research
Risk Factors and Pathogen Spectrum in Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis: A S...Med Sci Monit In Press; DOI: 10.12659/MSM.937112
11 Aug 2022 : Meta-Analysis
Optimal Surgical Treatment Method for Anterior Cruciate Ligament Rupture: Results from a Network Meta-AnalysisMed Sci Monit In Press; DOI: 10.12659/MSM.937118
10 Aug 2022 : Review article
Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and NecroptosisMed Sci Monit In Press; DOI: 10.12659/MSM.937766
10 Aug 2022 : Database Analysis
Use and Effects of Augmentation of Labor with Oxytocin: A Single-Center, Retrospective, Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.937557
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996